To Investigate the Relationship Between the Viscoelastic Properties of the Zona Pellucida of Human Oocyte and the Blastocyst Utilization Rate

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06839495

Enrollment

200

Registered

2025-02-21

Start date

2024-07-31

Completion date

2025-12-31

Last updated

2025-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oocyte, Viscoelastic Property, Zona Pellucida

Brief summary

In in vitro fertilization (IVF) treatment, oocyte quality is one of the key factors influencing the success rate of fertilization. The zona pellucida (ZP) is a spherical structure that surrounds the human oocyte and, together with cumulus cells, forms the cumulus-oocyte complex (COC). These two components engage in bidirectional communication and metabolic regulation to support oocyte growth and maturation. Additionally, the physical rigidity of the zona pellucida plays an important role in the fertilization process. OPAL X1 is a non-invasive and highly safe device specifically designed to measure the viscoelastic properties of the zona pellucida. This system consists of an ultra-precise pressure control mechanism and analytical software to assess oocyte quality before fertilization. OPAL X1 applies pressure through a micropipette while simultaneously recording the movement of the zona pellucida within the micropipette. An algorithm then analyzes the recorded motion images and classifies the oocytes into different quality grades (Grade A, B, C). This study aims to investigate the correlation between oocyte classification results obtained from the OPAL X1 grading system and oocyte quality. By integrating spindle-view and time-lapse technology, the study seeks to identify the optimal parameters for oocyte quality assessment. Furthermore, these findings will be applied to predict the success rate of intracytoplasmic sperm injection (ICSI), the likelihood of blastocyst formation, and pregnancy outcomes after embryo transfer. Ultimately, this study aims to provide more efficient and timely embryo development information before IVF, assisting clinicians in formulating and optimizing IVF treatment strategies.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

No minimum to 38 Years

Healthy volunteers

Yes

Inclusion criteria

1. Women who have started the in vitro fertilization (IVF) treatment and related examinations. 2. Female participants aged ≤38 years with an anti-Müllerian hormone (AMH) concentration greater than 1.1 ng/mL and a collected oocyte count of more than 10. 3. Participants who consent to undergoing IVF with intracytoplasmic sperm injection (ICSI) and time-lapse embryo culture.

Exclusion criteria

1. Women diagnosed with untreated uterine abnormalities as assessed by a physician. 2. Participants with a body mass index (BMI) outside the range of 18.5-30 kg/m\^2. 3. Patients undergoing IVF using sperm retrieved through surgical extraction. 4. Patients undergoing IVF using donated oocytes or donated sperm.

Design outcomes

Primary

Measure	Time frame	Description
Usable blastocyst rates	4 weeks	Usable blastocyst rates in each oocyte quality grading group.

Secondary

Measure	Time frame	Description
Pregnancy outcomes.	12 months	The correlation between oocyte quality grading groups and pregnancy outcomes.

Countries

Taiwan

Outcome results